OPINION: Chinese Healthcare Industry Entering A ‘New Normal’?
This article was originally published in PharmAsia News
Executive Summary
Two years after the GSK scandal broke in China, a national campaign against corruption is marching on in the country, and a series of recent events suggests that Chinese authorities are determined to clean up the healthcare industry and bring in a 'new normal'. For multinational companies, the shakeup should come as welcome news, and it is time to devise strategies to prepare for a new phase of reform in the country.
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.